Philip Nickson
General Counsel at MONTE ROSA THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Profile
Philip Nickson is currently working as the General Counsel at Monte Rosa Therapeutics, Inc. He previously worked as the Vice President-Intellectual Property at Momenta Pharmaceuticals, Inc. from 2012 to 2021.
Dr. Nickson holds a doctorate degree from The University of Manchester and a graduate degree from Suffolk University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-01 | 0 ( -.--% ) | - $ | 2024-04-29 |
Philip Nickson active positions
| Companies | Position | Start |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | General Counsel | 2021-02-28 |
Former positions of Philip Nickson
| Companies | Position | End |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2021-02-28 |
Training of Philip Nickson
| The University of Manchester | Doctorate Degree |
| Suffolk University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
| Monte Rosa Therapeutics, Inc. |
- Stock Market
- Insiders
- Philip Nickson